Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients
- Conditions
- Heart Failure
- Registration Number
- NCT01616121
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedance-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 654
- Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure
- Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Prevention of acute heart failure development in acute MI patients Three years
- Secondary Outcome Measures
Name Time Method Improvement of clinical outcome in patients with lung impedance-guided treatments Three years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel
Hillel Yaffe Medical Center🇮🇱Hadera, Israel